251 related articles for article (PubMed ID: 36282174)
1. Comprehensive machine-learning survival framework develops a consensus model in large-scale multicenter cohorts for pancreatic cancer.
Wang L; Liu Z; Liang R; Wang W; Zhu R; Li J; Xing Z; Weng S; Han X; Sun YL
Elife; 2022 Oct; 11():. PubMed ID: 36282174
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive analysis of the interaction of antigen presentation during anti-tumour immunity and establishment of AIDPS systems in ovarian cancer.
Sun W; Xu P; Gao K; Lian W; Sun X
J Cell Mol Med; 2024 Apr; 28(8):e18309. PubMed ID: 38613345
[TBL] [Abstract][Full Text] [Related]
3. Machine learning-based identification of a consensus immune-derived gene signature to improve head and neck squamous cell carcinoma therapy and outcome.
Hu X; Dong H; Qin W; Bin Y; Huang W; Kang M; Wang R
Front Pharmacol; 2024; 15():1341346. PubMed ID: 38666027
[TBL] [Abstract][Full Text] [Related]
4. Machine learning-derived identification of prognostic signature for improving prognosis and drug response in patients with ovarian cancer.
Huan Q; Cheng S; Ma HF; Zhao M; Chen Y; Yuan X
J Cell Mol Med; 2024 Jan; 28(1):e18021. PubMed ID: 37994489
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multicenter cohort study based on super-enhancer profiling.
Chen D; Cao Y; Tang H; Zang L; Yao N; Zhu Y; Jiang Y; Zhai S; Liu Y; Shi M; Zhao S; Wang W; Wen C; Peng C; Chen H; Deng X; Jiang L; Shen B
Theranostics; 2023; 13(10):3290-3309. PubMed ID: 37351165
[No Abstract] [Full Text] [Related]
6. Artificial intelligence-driven consensus gene signatures for improving bladder cancer clinical outcomes identified by multi-center integration analysis.
Xu H; Liu Z; Weng S; Dang Q; Ge X; Zhang Y; Ren Y; Xing Z; Chen S; Zhou Y; Ren J; Han X
Mol Oncol; 2022 Dec; 16(22):4023-4042. PubMed ID: 36083778
[TBL] [Abstract][Full Text] [Related]
7. Machine learning algorithm-generated and multi-center validated melanoma prognostic signature with inspiration for treatment management.
Liu Z; Xu H; Weng S; Guo C; Dang Q; Zhang Y; Ren Y; Liu L; Wang L; Ge X; Xing Z; Zhang J; Luo P; Han X
Cancer Immunol Immunother; 2023 Mar; 72(3):599-615. PubMed ID: 35998003
[TBL] [Abstract][Full Text] [Related]
8. Integrated machine learning identifies epithelial cell marker genes for improving outcomes and immunotherapy in prostate cancer.
Zhu W; Zeng H; Huang J; Wu J; Wang Y; Wang Z; Wang H; Luo Y; Lai W
J Transl Med; 2023 Nov; 21(1):782. PubMed ID: 37925432
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer.
Li B; Cui Y; Diehn M; Li R
JAMA Oncol; 2017 Nov; 3(11):1529-1537. PubMed ID: 28687838
[TBL] [Abstract][Full Text] [Related]
10. Construction of a 6-gene prognostic signature to assess prognosis of patients with pancreatic cancer.
Yang J; Shi W; Zhu S; Yang C
Medicine (Baltimore); 2020 Sep; 99(37):e22092. PubMed ID: 32925750
[TBL] [Abstract][Full Text] [Related]
11. Identification of a Tumor Microenvironment-relevant Gene set-based Prognostic Signature and Related Therapy Targets in Gastric Cancer.
Cai WY; Dong ZN; Fu XT; Lin LY; Wang L; Ye GD; Luo QC; Chen YC
Theranostics; 2020; 10(19):8633-8647. PubMed ID: 32754268
[No Abstract] [Full Text] [Related]
12. Integrated machine learning survival framework develops a prognostic model based on inter-crosstalk definition of mitochondrial function and cell death patterns in a large multicenter cohort for lower-grade glioma.
Qin H; Abulaiti A; Maimaiti A; Abulaiti Z; Fan G; Aili Y; Ji W; Wang Z; Wang Y
J Transl Med; 2023 Sep; 21(1):588. PubMed ID: 37660060
[TBL] [Abstract][Full Text] [Related]
13. Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer.
Guo Y; Wang R; Shi J; Yang C; Ma P; Min J; Zhao T; Hua L; Song Y; Li J; Su H
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37739440
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive machine learning-based preoperative blood features predict the prognosis for ovarian cancer.
Wu M; Gu S; Yang J; Zhao Y; Sheng J; Cheng S; Xu S; Wu Y; Ma M; Luo X; Zhang H; Wang Y; Zhao A
BMC Cancer; 2024 Feb; 24(1):267. PubMed ID: 38408960
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
16. The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients.
Osipov A; Nikolic O; Gertych A; Parker S; Hendifar A; Singh P; Filippova D; Dagliyan G; Ferrone CR; Zheng L; Moore JH; Tourtellotte W; Van Eyk JE; Theodorescu D
Nat Cancer; 2024 Feb; 5(2):299-314. PubMed ID: 38253803
[TBL] [Abstract][Full Text] [Related]
17. A DNA-Methylation-Driven Genes Based Prognostic Signature Reveals Immune Microenvironment in Pancreatic Cancer.
Xiao M; Liang X; Yan Z; Chen J; Zhu Y; Xie Y; Li Y; Li X; Gao Q; Feng F; Fu G; Gao Y
Front Immunol; 2022; 13():803962. PubMed ID: 35222383
[TBL] [Abstract][Full Text] [Related]
18. Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer.
Liu Z; Guo C; Dang Q; Wang L; Liu L; Weng S; Xu H; Lu T; Sun Z; Han X
EBioMedicine; 2022 Jan; 75():103750. PubMed ID: 34922323
[TBL] [Abstract][Full Text] [Related]
19. Radiomics in stratification of pancreatic cystic lesions: Machine learning in action.
Dalal V; Carmicheal J; Dhaliwal A; Jain M; Kaur S; Batra SK
Cancer Lett; 2020 Jan; 469():228-237. PubMed ID: 31629933
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
Front Immunol; 2021; 12():648917. PubMed ID: 33777046
[No Abstract] [Full Text] [Related]
[Next] [New Search]
